BarnettB, OstrovskyA. Psychedelic medicine's future depends on proactive development of a robust medical billing and coding strategy. Psychedelic Med, 2023; 1(1); doi: 10.1089/psymed.2022.0005
4.
Delphin-RittmonM. [SAMHSA response to Representative Madeleine Dean on the establishment of a Federal Task Force to address the approval of MDMA for the treatment of PTSD]. May 13, 2022. Available from: www.documentcloud.org/documents/22121426-exhibit-3-response-to-rep-dean-et-al [Last accessed: March31, 2024].
5.
MitchellJM, BogenschutzM, LiliensteinA, et al.MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med, 2021; 27:1025–1033; doi: 10.1038/s41591-021-01336-3
6.
MitchellJM, Ot'aloraGM, van der KolkB, et al.MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nat Med, 2023; 29(10);2473–2480; doi: 10.1038/s41591-023-02565-4
DalyEJ, SinghJB, FedgchinM, et al.Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 2018; 75(2):139–148; doi: 10.1001/jamapsychiatry.2017.3739
9.
GoodwinGM, AaronsonST, AlvarezO, et al.Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med, 2022; 387(18):1637–1648; doi: 10.1056/NEJMoa2206443
10.
BeschlossA, Van RamshorstR, BachireddyC, et al.New coding modifier offers opportunity to investigate audio-only telehealth. Health Aff Forefront, 2022; doi: 10.1377/forefront.20221117.43940
11.
ZhdanavaM, PilonD, ChelerterI, et al.The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry, 2021; 82(2); doi: 10.4088/JCP.20m13699
12.
IvanovaJI, BirnbaumHG, ChenL, et al.Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by Medicaid or private insurance. Am J Manag Care, 2011; 17(8).
WilkinsonST, ToprakM, TurnerMS, et al.A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry, 2017; 174(7):695–696; doi: 10.1176/appi.ajp.2017.17020239
16.
DoreJ, TurnipseedB, DwyerS, et al.Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoact Drugs, 2019; 51(2):189–198; doi: 10.1080/02791072.2019.1587556
